Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 10/20 | 0.51 |
| ▸ | TSHR | P16473 | 10/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | KYNU | Q16719 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18526738 | 1.00 | CYP3A4 (0.51) | CYP3A4TSHRALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL28700992 | 0.91 | CYP3A4 (0.47) | CYP3A4TSHRALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL28700994 | 0.91 | CYP3A4 (0.47) | CYP3A4TSHRALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL1162709 | 0.91 | CYP3A4 (0.48) | CYP3A4TSHRALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL22207625 | 0.91 | CYP3A4 (0.48) | CYP3A4TSHRALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL31582591 | 0.91 | CYP3A4 (0.48) | CYP3A4TSHRALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL26662871 | 0.89 | CYP3A4 (0.49) | CYP3A4TSHRALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL13209775 | 0.89 | KYNU (0.51) | CYP3A4TSHRALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL30672437 | 0.88 | DPP4 (0.48) | CYP3A4TSHRALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL22213837 | 0.87 | DPP4 (0.45) | CYP3A4TSHRALDH1A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-2513091-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2499132-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-2499115-B1 | PROCESS FOR PREPARING HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2016-07-27 | — | — | EP | disclosed |
| US-9303007-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| US-9303007-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| WO-2010120621-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010117704-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010117635-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010117977-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100260708-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-14 | — | — | US | disclosed |
| US-20100260708-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-14 | — | — | US | disclosed |
| US-20100249190-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
| US-20100249190-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | CYP3A4 1005/4885TSHR 4676/4885ALDH1A1 1107/4885 |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CYP3A4 1107/4885TSHR 4635/4885ALDH1A1 1144/4885 |
| US-20100249190-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | CYP3A4 3387/4885TSHR 4547/4885ALDH1A1 2120/4885 |
| US-20100260708-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CYP3A4 1107/4885TSHR 4635/4885ALDH1A1 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.